NCT04022733 is a NA clinical trial of Moderate neuromuscular block in Hernia Abdominal Wall, sponsored by Ajou University School of Medicine.

Who is sponsoring NCT04022733?

NCT04022733 is sponsored by Ajou University School of Medicine.

What drugs are being tested in NCT04022733?

Interventions in NCT04022733: Moderate neuromuscular block, Deep neuromuscular block.

What condition does NCT04022733 study?

NCT04022733 studies Hernia Abdominal Wall.

Is NCT04022733 still recruiting?

NCT04022733 is currently completed. Last updated 9 November 2023.

Are results published for NCT04022733?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-11-09 · How we verify

NCT04022733

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remifentanil in Deep vs Moderate Neuromuscular Blocks During Surgical Pleth Index-guided Anesthesia for Laparoscopic Herniorrhaphy

Completed NA Results posted Last updated 9 November 2023

What this trial tests

NA trial testing Moderate neuromuscular block in Hernia Abdominal Wall in 134 participants. Completed in 3 August 2021.

Timeline

30 October 2019

Primary endpoint
3 August 2021

3 August 2021

Quick facts

Lead sponsor	Ajou University School of Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	134
Start date	30 October 2019
Primary completion	3 August 2021
Estimated completion	3 August 2021
Sites	1 location across South Korea

Drugs / interventions tested

Moderate neuromuscular block — full drug profile →
Deep neuromuscular block — full drug profile →

Conditions studied

Hernia Abdominal Wall — all drugs for Hernia Abdominal Wall →

Sponsor

Ajou University School of Medicine

Who can join

Adults 19 to 85, any sex, with Hernia Abdominal Wall. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Remifentanil Infusion Rate Primary · from pneumoperitoneum to removal of laparoscope, an average of 30 minutes

remifentanil infusion using target effect-site concentration to achieve an surgical pleth index of range between 25 and 50

Group	Value	95% CI
Moderate NMB Group	0.103	0.075 – 0.143
Deep NMB Group	0.073	0.056 – 0.097

Sponsor's own description

The primary purpose of this study is to compare the remifentanil requirements in deep versus moderate neuromuscular blocks during the surgical pleth index -guided anesthesia in patients undergoing laparoscopic herniorrhaphy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of deep neuromuscular block on surgical pleth index-guided remifentanil administration in laparoscopic herniorrhaphy: a prospective randomized trial.
Yi IK, Kim JS, Hur H, Han DG, et al · · 2022 · cited 4× · PMID 36357559 · DOI 10.1038/s41598-022-23876-5

Verify or expand the search:

Other trials of Moderate neuromuscular block

Trials testing the same drug.

NCT06242262 — Deep Neuromuscular Block With Low Pressure Pneumoperitoneum in Laparoscopic Abdominal Surgeries · NA · completed
NCT03643913 — The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity i · Phase 4 · completed
NCT03576118 — Moderate vs Deep Neuromuscular Block on Biotrauma During Laparoscopy · NA · completed

Other recruiting trials for Hernia Abdominal Wall

Currently open trials in the same condition.

NCT07220382 — Preoperative BOTOX® Injection for Large Ventral Hernia Repair · Phase 4 · recruiting
NCT06449378 — Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia · NA · active not recruiting
NCT06051578 — Abdominal Wall Tension in Patients Undergoing Ventral Hernia Repair Without Component Separation · active not recruiting
NCT05734222 — Optimization of Surgical Treatment of Patients With Incisional Ventral Hernias · NA · recruiting

Other Ajou University School of Medicine trials

Trials by the same sponsor.

NCT07101380 — Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients · NA · recruiting
NCT07395752 — Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study · NA · recruiting
NCT06964217 — Immediate Fracture Risk After Antihypertensive Drug Initiation · not yet recruiting
NCT05751603 — Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex · NA · not yet recruiting
NCT07479160 — Heart to Heart Web-based Communication Program for Heart Failure · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04022733 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ajou University School of Medicine
Last refreshed: 9 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04022733.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing